What is ICB International?
ICB International operates at the intersection of advanced pharmacology and neurology, utilizing its proprietary SMART Molecule Technology Platform to address critical gaps in the treatment of neurodegenerative conditions. The company focuses on overcoming the physiological challenges of the blood-brain barrier, a primary obstacle in delivering effective therapeutics for Alzheimer's and Parkinson's disease. Since its inception in 2008, the organization has cultivated a robust intellectual property portfolio, positioning itself as a key innovator in the development of biologics that target pathological proteins within the central nervous system. By prioritizing both early diagnostic capabilities and therapeutic intervention, ICB International addresses a global patient population of approximately 65 million, aiming to transform the standard of care for chronic brain disorders.
How much funding has ICB International raised?
ICB International has raised a total of $52K across 1 funding round:
Debt
$52K
Debt (2021): $52K with participation from PPP
Key Investors in ICB International
PPP
Public-Private Partnership
What's next for ICB International?
With the recent influx of capital, ICB International is expected to transition into a more aggressive phase of clinical validation and operational scaling. The strategic deployment of these funds will likely focus on advancing lead candidates through human trials and expanding the reach of its SMART Molecule platform. As the company moves deeper into its Series B/C lifecycle, the focus will shift toward regulatory milestones and potential commercialization partnerships. Investors and industry stakeholders will be monitoring the firm's ability to translate its extensive patent research into tangible clinical outcomes, which remains the primary catalyst for long-term value creation in the high-stakes biotech sector.
See full ICB International company page
